Study tracks patterns of US cases of anal canal carcinoma

April 2, 2013
Study tracks patterns of U.S. cases of anal canal carcinoma
Available screening and identification of human papillomavirus likely contributed to the increased incidences of squamous cell carcinoma of the anal canal (SCCA) and anal carcinoma in situ (CIS) after 1997, according to research published online March 18 in Journal of Clinical Oncology.

(HealthDay)—Available screening and identification of human papillomavirus likely contributed to the increased incidences of squamous cell carcinoma of the anal canal (SCCA) and anal carcinoma in situ (CIS) after 1997, according to research published online March 18 in Journal of Clinical Oncology.

Rebecca A. Nelson, of the City of Hope National Medical Center in Duarte, Calif., and colleagues analyzed data from the Surveillance, Epidemiology, and End Results Program to determine the incidence trends from 1973 to 2009.

According to the researchers, the slope of the incidence rates increased significantly in 1997 with a risk ratio (RR) of 2.2, when they compared the incidences between 1997 to 2009 and 1973 to 1996. Annual percent changes increased significantly for all stages of SCCA and was the greatest for anal carcinoma in situ (CIS). After 1997, RR was significantly higher in women than in men for localized (1.2) and regional stages of SCCA (1.5), but significantly lower for CIS (0.3). Adenocarcinoma annual percent changes remained stable during this time period.

"This study is the first to demonstrate the dramatic rise in incidence of CIS and SCCA in the context of the stable rates of adenocarcinoma in situ and anal adenocarcinoma," the authors write. "We suggest that high-risk men as well as women with high-grade anogenital HPV-related epithelial changes be considered for anal ."

Explore further: Despite cART, anal cancer risk still high for HIV-infected

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Despite cART, anal cancer risk still high for HIV-infected

December 13, 2012
(HealthDay)—For HIV-infected patients, despite combined antiretroviral treatment (cART), the risk of anal cancer is still much higher than in the general population, according to a study published in the Dec. 10 issue of ...

HIV raises anal cancer risk in women, study says

April 16, 2012
(HealthDay) -- Women with HIV are at increased risk for anal cancer, a new study finds.

HIV helps explain rise of anal cancer in US males

October 6, 2012
The increase in anal cancer incidence in the U.S. between 1980 and 2005 was greatly influenced by HIV infections in males, but not females, according to a study published October 5 in the Journal of the National Cancer Institute.

Most anal lesions don't cause cancer in men, research shows

March 23, 2012
(HealthDay) -- Anal human papillomavirus (HPV) infection and precancerous lesions are common among gay and bisexual men, but most of these cases will not progress to anal cancer, a new analysis of earlier research shows.

Cervical vaccine also protects against anal cancer risk

August 23, 2011
A vaccine routinely used to shield against cervical cancer caused by the human papillomavirus also reduces women's risk of anal cancer, a study published by the journal The Lancet Oncology on Tuesday says.

Researchers uncover new potential biomarker and therapeutic target for aggressive breast cancer

April 29, 2011
(PhysOrg.com) -- In an analysis of more than 1,300 human breast tissue samples, a team of Stony Brook University School of Medicine researchers discovered a possible role of the squamous cell carcinoma antigen (SCCA) in the ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.